We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma.
- Authors
Yuan, Jeng-Nian; Chao, Yee; Lee, Wei-Ping; Li, Chung-Pin; Lee, Rheun-Chuan; Chang, Full-Young; Yen, Sang-Hue; Lee, Shou-Dong; Whang-Peng, Jacqueline
- Abstract
<bold>Background: </bold>To investigate the therapeutic index of combining etoposide, doxorubicin (adriamycin), cisplatin, 5-fluorouracil (5-FU), and leucovorin (EAPFL) chemotherapy in the treatment of advanced HCC, a trial of a novel schedule of triweekly administration was conducted.<bold>Patients and Methods: </bold>Sixty-six patients with measurable advanced HCC, adequate liver and renal functions and adequate bone marrow reserves in whom local treatment was not indicated were studied. Triweekly EAPFL treatment consisted of a concomitant boost of etoposide 40 mg/m2 i.v. over 30 min on day 1, 2, and 3, doxorubicin 30 mg/m2 i.v. over 30 min on day 1 to a backbone regimen, triweekly PFL chemotherapy with cisplatin 60 mg/m2, 5-FU 1,200 mg/m2, and leucovorin 120 mg/m2 given simultaneously by a 72-h i.v. infusion. Response, survival, and toxicity were evaluated.<bold>Results: </bold>One patient had complete response (1%) and thirteen patients had partial response (20%). The objective response rate was 21% (95% confidence interval 11-31%). The median overall survival and median time to progression were 8.9 months and 3.3 months, respectively. Major treatment toxicities (grade 3-4) were neutropenia (28%), anemia (11%), thrombocytopenia (7%), hepatotoxicity (5%), vomiting (2%), and diarrhea (2%). There was no treatment-related death.<bold>Conclusion: </bold>Triweekly EAPFL chemotherapy is a moderately effective regimen with tolerable toxicities in the treatment of advanced HCC.
- Subjects
ANTINEOPLASTIC agents; CISPLATIN; CLINICAL trials; COMPARATIVE studies; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC acid; HEPATOCELLULAR carcinoma; LIVER tumors; RESEARCH methodology; MEDICAL cooperation; RESEARCH; EVALUATION research
- Publication
Medical Oncology, 2008, Vol 25, Issue 2, p201
- ISSN
1357-0560
- Publication type
journal article
- DOI
10.1007/s12032-007-9013-3